Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
Cryopreservation of chimeric antigen receptor (CAR) T cells facilitates shipment, timing of infusions, and storage of subsequent doses. However, reports on the impact of cryopreservation on CAR T cell efficacy have been mixed. We retrospectively compared clinical outcomes between patients who receiv...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-03-01
|
Series: | Molecular Therapy: Methods & Clinical Development |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2329050122001772 |
_version_ | 1797978784109953024 |
---|---|
author | Alexandra Dreyzin Sandhya R. Panch Haneen Shalabi Bonnie Yates Steven L. Highfill Ping Jin David Stroncek Nirali N. Shah |
author_facet | Alexandra Dreyzin Sandhya R. Panch Haneen Shalabi Bonnie Yates Steven L. Highfill Ping Jin David Stroncek Nirali N. Shah |
author_sort | Alexandra Dreyzin |
collection | DOAJ |
description | Cryopreservation of chimeric antigen receptor (CAR) T cells facilitates shipment, timing of infusions, and storage of subsequent doses. However, reports on the impact of cryopreservation on CAR T cell efficacy have been mixed. We retrospectively compared clinical outcomes between patients who received cryopreserved versus fresh CAR T cells for treatment of B cell leukemia across two cohorts of pediatric and young adult patients: those who received anti-CD22 CAR T cells and those who received bispecific anti-CD19/22 CAR T cells. Manufacturing methods were consistent within each trial but differed between the two trials, allowing for exploration of cryopreservation within different manufacturing platforms. Among 40 patients who received anti-CD22 CAR T cells (21 cryopreserved cells and 19 fresh), there were no differences in in vivo expansion, persistence, incidence of toxicities, or disease response between groups with cryopreserved and fresh CAR T cells. Among 19 patients who received anti-CD19/22 CAR T cells (11 cryopreserved and 8 fresh), patients with cryopreserved cells had similar expansion, toxicity incidence, and disease response, with decreased CAR T cell persistence. Overall, our data demonstrate efficacy of cryopreserved CAR T cells as comparable to fresh infusions, supporting cryopreservation, which will be crucial for advancing the field of cell therapy. |
first_indexed | 2024-04-11T05:28:31Z |
format | Article |
id | doaj.art-b7798ef47ea843b29b8ef539a38ccb2c |
institution | Directory Open Access Journal |
issn | 2329-0501 |
language | English |
last_indexed | 2024-04-11T05:28:31Z |
publishDate | 2023-03-01 |
publisher | Elsevier |
record_format | Article |
series | Molecular Therapy: Methods & Clinical Development |
spelling | doaj.art-b7798ef47ea843b29b8ef539a38ccb2c2022-12-23T04:41:13ZengElsevierMolecular Therapy: Methods & Clinical Development2329-05012023-03-01285161Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cellsAlexandra Dreyzin0Sandhya R. Panch1Haneen Shalabi2Bonnie Yates3Steven L. Highfill4Ping Jin5David Stroncek6Nirali N. Shah7Center for Cancer and Blood Disorders, Children’s National Hospital, Washington, DC 20010, USADivision of Hematology, Hutchinson Cancer Center, University of Washington, Seattle, WA 98109, USAPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USAPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USADepartment of Transfusion Medicine and Cellular Engineering, Center for Cellular Engineering, NIH Clinical Center, NIH, Bethesda, MD 20892, USADepartment of Transfusion Medicine and Cellular Engineering, Center for Cellular Engineering, NIH Clinical Center, NIH, Bethesda, MD 20892, USADepartment of Transfusion Medicine and Cellular Engineering, Center for Cellular Engineering, NIH Clinical Center, NIH, Bethesda, MD 20892, USA; Corresponding author David Stroncek, MD, Department of Transfusion Medicine and Cellular Engineering, Center for Cellular Engineering, NIH Clinical Center, NIH, Building 10, Room 1C711, 10 Center Drive, Bethesda, MD 20892, USA.Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA; Corresponding author Nirali N. Shah, MD, MHSc, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 1W-3750, 9000 Rockville Pike MSC 1104, Bethesda, MD 20892, USA.Cryopreservation of chimeric antigen receptor (CAR) T cells facilitates shipment, timing of infusions, and storage of subsequent doses. However, reports on the impact of cryopreservation on CAR T cell efficacy have been mixed. We retrospectively compared clinical outcomes between patients who received cryopreserved versus fresh CAR T cells for treatment of B cell leukemia across two cohorts of pediatric and young adult patients: those who received anti-CD22 CAR T cells and those who received bispecific anti-CD19/22 CAR T cells. Manufacturing methods were consistent within each trial but differed between the two trials, allowing for exploration of cryopreservation within different manufacturing platforms. Among 40 patients who received anti-CD22 CAR T cells (21 cryopreserved cells and 19 fresh), there were no differences in in vivo expansion, persistence, incidence of toxicities, or disease response between groups with cryopreserved and fresh CAR T cells. Among 19 patients who received anti-CD19/22 CAR T cells (11 cryopreserved and 8 fresh), patients with cryopreserved cells had similar expansion, toxicity incidence, and disease response, with decreased CAR T cell persistence. Overall, our data demonstrate efficacy of cryopreserved CAR T cells as comparable to fresh infusions, supporting cryopreservation, which will be crucial for advancing the field of cell therapy.http://www.sciencedirect.com/science/article/pii/S2329050122001772cell therapyCAR Tclinical outcomescryopreservationCAR T manufacturingcytokine release syndrome |
spellingShingle | Alexandra Dreyzin Sandhya R. Panch Haneen Shalabi Bonnie Yates Steven L. Highfill Ping Jin David Stroncek Nirali N. Shah Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells Molecular Therapy: Methods & Clinical Development cell therapy CAR T clinical outcomes cryopreservation CAR T manufacturing cytokine release syndrome |
title | Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells |
title_full | Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells |
title_fullStr | Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells |
title_full_unstemmed | Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells |
title_short | Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells |
title_sort | cryopreserved anti cd22 and bispecific anti cd19 22 car t cells are as effective as freshly infused cells |
topic | cell therapy CAR T clinical outcomes cryopreservation CAR T manufacturing cytokine release syndrome |
url | http://www.sciencedirect.com/science/article/pii/S2329050122001772 |
work_keys_str_mv | AT alexandradreyzin cryopreservedanticd22andbispecificanticd1922cartcellsareaseffectiveasfreshlyinfusedcells AT sandhyarpanch cryopreservedanticd22andbispecificanticd1922cartcellsareaseffectiveasfreshlyinfusedcells AT haneenshalabi cryopreservedanticd22andbispecificanticd1922cartcellsareaseffectiveasfreshlyinfusedcells AT bonnieyates cryopreservedanticd22andbispecificanticd1922cartcellsareaseffectiveasfreshlyinfusedcells AT stevenlhighfill cryopreservedanticd22andbispecificanticd1922cartcellsareaseffectiveasfreshlyinfusedcells AT pingjin cryopreservedanticd22andbispecificanticd1922cartcellsareaseffectiveasfreshlyinfusedcells AT davidstroncek cryopreservedanticd22andbispecificanticd1922cartcellsareaseffectiveasfreshlyinfusedcells AT niralinshah cryopreservedanticd22andbispecificanticd1922cartcellsareaseffectiveasfreshlyinfusedcells |